Immediate transfection of patient-derived leukemia: A novel source for generating cell-based vaccines

Genetic Vaccines and Therapy

Volumn 3, Issue , 2005, Pages

  Gershan, Jill A ^a   Johnson, Bryon D ^a   Weber, James ^a   Schauer, Dennis W ^a   Natalia, Natalia ^a   Behnke, Stephanie ^a   Burns, Karen ^a   Maloney, Kelly W ^a   Warwick, Anne B ^a   Orentas, Rimas J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; PLASMID DNA; PLASMID VECTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL DIVISION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSGENE;

ANIMALIA; MURINAE;

EID: 27344454702     PISSN: 14790556     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-3-4     Document Type: Article

References (15)

1. Hock RA, Reynolds BD, Tucker-McClung CL, Kwok WW: Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother 1995, 17:12-8.
2. Bausero MA, Panoskaltsis-Mortari A, Blazar BR, Katsanis E: Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. J Immunother 1996, 19:113-24.
3. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR: Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 1997, 15:81-90.
4. Johnson BD, Yan X, Schauer DW, Orentas RJ: Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 2003, 222:15-26.
5. Yan X, Johnson BD, Orentas RJ: Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumor-reactive effector cells in vivo. Immunol 2004, 112:105-116.
6. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D: Part I: Vaccines for solid tumors. Lancet Oncol 2004, 5:681-689.
7. Rousseau RF, Haight AE, Hirschmann-Jax C, et al.: Local and systemic effects of an allogeneic tumor cell vaccine combining human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003, 101:1718-1726.
8. Schakowski F, Buttgereit P, Mazur M, et al: Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther 2004, 2:1-11.
9. Sanburn N, Cornetta K. Rapid titer determination using quantitative real-time PCR. Gene Ther 1999, 6:1340-1345.
10. Perry C, Sastry R, Masrallah IM, Stover PJ: Mimosine attenuates serine hydroxymethyltransferase transcription by chelating zinc. J Biol Chem 2005, 280:396-400.
11. Tlsty T, Briot A, Poulose B: Analysis of cell cycle checkpoint status in mammalian cells. Methods Enzymol 1995, 254:125-133.
12. Bevis BJ, Glick BS: Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat Biotechnol 2002, 20:83-87.
13. Mocellin S, Rossi CR, Nitti D: Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 2004, 299:267-78.
14. Brunner S, Fürtbauer E, Sauer T, Kursa M, Wagner E: Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther 2002, 5:80-86.
15. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Shan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998, 95:13141-13146.